ストックスクリーナーアプリを入手
1.96
51.94%
0.67
プレマーケット:
1.96
前日終値:
$1.29
開ける：
$1.31
24時間の取引高:
7.75M
Relative Volume:
11.79
時価総額：
$134.01M
収益：
-
当期純損益:
$-60.36M
株価収益率:
-0.4461
EPS:
-4.394
ネットキャッシュフロー:
$-15.05M
1週間 パフォーマンス:
+41.01%
1か月 パフォーマンス:
+71.93%
6か月 パフォーマンス:
+10.73%
1年 パフォーマンス:
-44.00%
1日の値動き範囲:
$1.3063
$1.96
1週間の範囲:
$1.26
$1.96
52週間の値動き範囲:
$0.97
$5.07
Zura Bio Ltd Stock (ZURA) Company Profile
ZURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.96 | 86.01M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-04 | 開始されました | Leerink Partners | Outperform |
| 2024-09-05 | 開始されました | H.C. Wainwright | Neutral |
| 2024-05-03 | 開始されました | Piper Sandler | Overweight |
| 2023-10-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-08-25 | 開始されました | Oppenheimer | Outperform |
| 2023-06-22 | 開始されました | Guggenheim | Buy |
| 2023-06-14 | 開始されました | Chardan Capital Markets | Buy |
| 2023-05-24 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Zura Bio Ltd (ZURA) 最新ニュース
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zura Bio Surges 30% in Volatile Intraday Session: What's Fueling the Momentum? - AInvest
What makes Zura Bio Limited stock price move sharplyConsistent Growth Alert - Newser
How Zura Bio Limited stock performs during market volatilityProven Return Strategy Execution - Newser
Why Zura Bio Limited stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate - Yahoo Finance
The ZURA Stock Puzzle: Unraveling Zura Bio Ltd’s Fluctuating Performance - investchronicle.com
Zura Bio appoints Eric Hyllengren as CFO - MSN
Zura Bio names Eric Hyllengren as new CFO, effective July 7 - Investing.com
Zura Bio Announces Chief Financial Officer Transition - Eagle-Tribune
Zura Bio Limited(NasdaqCM: ZURA) dropped from Russell 2000 Dynamic Index - MarketScreener
Two Sigma Investments LP Decreases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Analysts Set Expectations for Zura Bio FY2026 Earnings - Defense World
Squarepoint Ops LLC Cuts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA Announces Upcoming Conference Call Hosted by Piper Sandler - GuruFocus
ZURA Announces Upcoming Conference Call Hosted by Piper Sandler | ZURA Stock News - GuruFocus
Two Sigma Advisers LP Invests $32,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Northern Trust Corp Has $1.01 Million Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts - Defense World
Zura Bio to Present at the Jefferies Global Healthcare Conference - Yahoo Finance
Zura Bio to Present at the Jefferies Global Healthcare Conference 2025 - BioSpace
Zura Bio shareholders approve board nominees and auditor - Investing.com Australia
Zura Bio shareholders approve board nominees and auditor By Investing.com - Investing.com South Africa
Q1 Earnings Forecast for Zura Bio Issued By HC Wainwright - Defense World
Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa - Clinical Trials Arena
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment - Investing.com Australia
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment By Investing.com - Investing.com India
Zura Bio (ZURA) Initiates Phase 2 Study for Tibulizumab in HS Treatment | ZURA Stock News - GuruFocus
Cubist Systematic Strategies LLC Makes New $62,000 Investment in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa - Quantisnow
Dimensional Fund Advisors LP Acquires New Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Wells Fargo & Company MN Grows Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Barclays PLC Boosts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Raymond James Financial Inc. Invests $371,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $17.00 - Defense World
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheime - GuruFocus
ZURA: Oppenheimer Revises Price Target Amid Ongoing Trials | ZUR - GuruFocus
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheimer | ZURA Stock News - GuruFocus
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance
Ratio Analysis: Unpacking Zura Bio Ltd (ZURA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Zura Bio Ltd Inc. (ZURA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Do investors need to be concerned about Zura Bio Ltd (ZURA)? - uspostnews.com
Geode Capital Management LLC Increases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Yahoo
ZURA overperforms with a 8.76 increase in share price - uspostnews.com
Zura Bio Limited (NASDAQ:ZURA) Receives $14.67 Average Price Target from Analysts - Defense World
HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings - Defense World
HC Wainwright Lowers Zura Bio (NASDAQ:ZURA) Price Target to $3.00 - Defense World
ZURA stock touches 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
Zura Bio Ltd (ZURA) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):